Hubei Biocause Pharmaceutical to invest in propylene production

Hubei Biocause Pharmaceutical plans to to invest 301.96 mln yuan in propylene production, which uses the process of catalytic cracking of C4 olefin. About 200.02 mln yuan will be earmarked for construction costs and 101.94 mln yuan for working capital. Capacities at the plant will comprise 21,800 tons of propylene, 10,000 tons of propane and 120,000 tons of liquefied natural gas.
  More News  Post Your Comment

Previous News

Next News

{{comment.Name}} made a post.




There are no comments to display. Be the first one to comment!


Name Required.


Email Id Required.

Email Id Not Valid.


Mobile Required.

Email ID and Mobile Number are kept private and will not be shown publicly.

Message Required.

Click to Change image  Refresh Captcha